Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Trading Update

18 Oct 2019 07:00

RNS Number : 3094Q
Itaconix PLC
18 October 2019
 

18 October 2019

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

Itaconix plc ("Itaconix" or the "Company")

Trading Update

Itaconix, a leading innovator in sustainable specialty polymers, provides an update on trading for the year ending 31 December 2019.

Revenues for the first three quarters of 2019 ended 30 September 2019 reached £0.7m, representing a 78% increase over revenues for the first three quarters of 2018 and matching full-year 2018 revenues of £0.7m. This growth demonstrates the value of the Company's products in detergents, personal care, and odour control. The Board expects second half revenues will exceed the first half of 2019. However, as a result of delays in certain customer projects, the Board believes that full-year revenues will be below current market expectations, but still represent a very significant increase over 2018 revenues. The Company continues to have a strong pipeline of active customer projects and is undertaking efforts to accelerate key revenue opportunities, particularly in water treatment and detergents.

As a result of lower than expected revenues and also some one-off costs related to new product development, the Board expects that the EBITDA(1) loss for the second half of the year will be broadly in line with the £1.0m loss for the first half of the year, which will be a substantial improvement over the £3.9m EBITDA loss for 2018.

Other than an R&D tax credit of c. £0.13 million, which is now expected to be received in early 2020 rather than in the current year, the Board believes that year-end cash will be in line with expectations due to significant improvements in working capital utilization.

John R. Shaw, CEO of Itaconix, stated: "The use of our novel products in an increasing range of end-products is establishing a broad customer base for long-term revenue growth and ultimate profitability. While project delays can be rather frustrating, our commercial momentum continues to build, we remain confident about our outlook, and our future remains equally bright."

1 Earnings before interest, tax, depreciation and amortisation.

Ends

For further information please contact:

Itaconix

+1 (603) 775 4400

 

John R. Shaw

N+1 Singer

+44 (0) 207 496 3000

Richard Lindley / James Moat (Corporate Finance)

Mia Gardner (Corporate Broking)

 

About Itaconix

Itaconix plc is a leading innovator in bio-based functional ingredients for improving the safety and performance of homecare, personal care, and industrial products. Its proprietary polymer technology generates a growing range of new ingredients with unique functionality that meet consumer demands for value and sustainability.

www.itaconix.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTDGBDGXGBBGCR
Date   Source Headline
2nd Jun 20267:00 amRNSMello 2026 Presentation and Update on Trading
1st Jun 20267:00 amRNS-RProgress in Crop Production Field Trials
29th May 20267:00 amRNS-RDevelopment of Next Generation Plant-Based Paints
27th May 20267:00 amRNS-RLaunch of New Marketing Program for Detergents
14th May 20265:55 pmRNSAdjournment of AGM
6th May 20264:46 pmRNSDirector/PDMR Shareholding
27th Apr 20266:16 pmRNSTR-1
23rd Apr 20267:00 amRNSGrants of Options & PDMR dealings
24th Mar 20267:00 amRNSPreliminary Results
28th Jan 20267:00 amRNSTR-1
16th Jan 20265:29 pmRNSDirector/PDMR Shareholding
13th Jan 20267:00 amRNSFull Year Trading Update
15th Sep 20257:00 amRNSHalf Year Results
4th Sep 20257:00 amRNSNotice of Interim Results
27th Aug 20258:19 amRNSTR-1
23rd Jul 20257:00 amRNSH1 2025 Trading Update
16th Jul 20257:00 amRNS-RCroda expands agreement: sustainable odour control
1st Jul 20257:00 amRNS-RCommercial Plant-Based Product Launch
8th May 20252:20 pmRNSResult of AGM
6th May 202512:24 pmRNSTR-1
2nd May 20255:28 pmRNSNotice of AGM
1st May 20257:00 amRNSUpdate on US Tariffs
7th Apr 20257:00 amRNSGrants of Options & PDMR dealings
31st Mar 20257:00 amRNSPreliminary Results
18th Mar 20257:00 amRNSNotice of Results and Company Presentation
22nd Jan 20257:00 amRNSTrading Update
5th Nov 20247:00 amRNSTrading Update
10th Oct 20247:00 amRNSChange of Auditor
10th Sep 20247:00 amRNSHalf Year Results
2nd Sep 20247:00 amRNSNotice of Interim Results, Investor Presentation
16th Jul 20247:00 amRNSH1 2024 Trading Update
20th May 20243:03 pmRNSResult of AGM
20th May 20247:00 amRNSAGM Statement and Trading Update
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.